Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

Anna Tasidou, Maria Roussou, Evangelos Terpos, Efstathios Kastritis, Maria Gkotzamanidou, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Nikitas Nikitas, Dimitra Anagnostou, Meletios A. Dimopoulos*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Abstract

Multiple myeloma (MM) comprises 1% of all malignancies and 13% of hematological malignancies in the Caucasian population. Yearly incidence is 4/100,000 in the US and is higher in blacks and males [1]. The pathogenesis of the disease is relatively unknown; several chromosomal abnormalities have been related to the development of the disease, but none is characteristic of MM. Cyclin-D1 is a protein encoded by the CCND1 (bcl-1) gene on chromosome 11q13, and is an important regulator of G1 to S phase progression.

Original languageEnglish
Pages (from-to)734-736
Number of pages3
JournalAmerican Journal of Hematology
Volume87
Issue number7
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents'. Together they form a unique fingerprint.

Cite this